

1 **Cross-Cultural Adaptation and Validation of the 5C Scale to Identify Factors Associated**
2 **With COVID-19 and Influenza Vaccine Hesitancy Among Healthcare Workers in Cape**
3 **Town, South Africa – A Protocol**

4
5 **Short Title: Measuring Vaccine Hesitancy Among Healthcare Workers in Cape Town**

6
7 Samuel M Alobwede^{a,b}, Patrick DMC Katoto^{c,d}, Sara Cooper^{c,e,f}, Evelyn N Lumngwena^{g,h},
8 Elvis B Kidzeru^{i,j,k}, Rene Goliath^l, Amanda Jackson^l, Charles S Wiysonge^{c,e,f,m,*}, Muki S
9 Shey^{a,l,n,*,#}

10

11 Affiliations:

12 ^a Department of Medicine, Faculty of Health Sciences and Groote Schuur Hospital, University
13 of Cape Town, Cape Town, South Africa

14 ^b Department of Research and Innovation, Clinical division, Partners in Sexual Health, Cape
15 Town, South Africa.

16 ^c Cochrane South Africa, South African Medical Research Council, Francie van Zijl Drive,
17 Parow Valley, Cape Town, South Africa

18 ^d Centre for General Medicine and Global Health, Department of Medicine, University of Cape
19 Town, Cape Town, South Africa

20 ^e Department of Global Health, Stellenbosch University, Cape Town, South Africa

21 ^f School of Public Health and Family Medicine, University of Cape Town, Cape Town, South
22 Africa

23 ^g School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand,
24 Johannesburg, South Africa

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 ^h Centre for the Study of Emerging and Re-emerging Infections (CREMER), Institute of
26 Medical Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and
27 Innovation, Yaoundé, Cameroon

28 ⁱ Centre for Research on Health and Priority Pathologies (CRHPP), Institute of Medical
29 Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and
30 Innovation, Yaoundé, Cameroon

31 ^j Hair and Skin Research Laboratory, Division of Dermatology, Department of Medicine,
32 Faculty of Health Sciences and Groote Schuur Hospital, University of Cape Town, Cape Town,
33 South Africa

34 ^k Division of Radiation Oncology, Department of Radiation Medicine, Faculty of Health
35 Science, University of Cape Town, and Groote Schuur Hospital, Cape Town, South Africa

36 ^l Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa), Faculty of Health
37 Sciences, University of Cape Town, Cape Town, South Africa

38 ^m HIV and other Infectious Diseases Research Unit, South African Medical Research Council,
39 Durban, South Africa

40 ⁿ Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences,
41 University of Cape Town, Cape Town, South Africa

42

43 *These authors contributed equally to this work.

44

45 #Corresponding author: A/Professor Muki S Shey, Department of Medicine & Wellcome
46 Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious
47 Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town,
48 Cape Town, South Africa. Email: muki.shey@uct.ac.za; Tel: +27 21 650 1731

49

50

51

52 **Abstract**

53 **Background:** Healthcare workers are at an increased risk of acquiring vaccine-preventable
54 diseases and are known to be reliable source of information for the patients and their relatives.
55 Knowledge and attitudes of Healthcare workers about vaccines are thus important determinants
56 of their own vaccination uptake and their intention to recommend vaccinations to their patients.
57 However, culturally adapted tools and studies to address vaccine uptake and hesitancy as well
58 as related behaviours among Healthcare workers in the Global South are limited.

59 **Methods:** We propose a mixed methods project to understand the extent and determinants of
60 vaccination hesitancy among Healthcare workers and construct a validated scale to measure
61 this complex and context-specific phenomenon in Cape Town. We will summarise responses
62 as counts and percentages for categorical variables and means with standard deviations (or
63 median with inter quartile ranges) for continuous variables. We will run the Shapiro-Wilks test
64 to assess the normality. Analysis of the variance, chi-square tests, and equivalents will be
65 conducted as appropriate for group comparisons. Logistic regression models will also be
66 performed to assess association between variables.

67 We will focus on the seasonal influenza and COVID-19 vaccine. We will use an existing tool
68 developed and validated in Germany and the United States of America to measure five
69 psychological determinants of vaccination (referred to as the 5C scale), as the basis to develop
70 and validate a scale to measure the scope and determinants of vaccine hesitancy and acceptance
71 among Healthcare workers in Cape Town.

72 **Discussion and conclusion:** Through this study, we hope to expand the scientific evidence
73 based on vaccination acceptance and demand among Healthcare workers in South Africa and

74 build resources to enable better understanding of, detection, and response to vaccination

75 hesitancy in Cape Town.

76

77 **Keywords:** COVID-19 vaccines, Influenza vaccines, vaccine attitudes, vaccine confidence,

78 vaccine hesitancy, healthcare workers, Cape Town.

80 **Background**

81 The World Health Organization (WHO) identified vaccine hesitancy (also referred to as
82 vaccination hesitancy) as one of the top ten threats to global health in 2019 (1, 2, 3). Vaccination
83 hesitancy refers to the delay in acceptance or refusal of vaccines, despite availability of
84 vaccination services. Vaccination hesitancy is complex and context-specific, varying across
85 time, place, and vaccines (4). We use the terms vaccine hesitancy and vaccination hesitancy
86 interchangeably in this proposal, to refer to the same phenomenon. The National Advisory
87 Group on Immunization (NAGI) in South Africa has identified both vaccination of healthcare
88 workers (HCWs) and vaccination hesitancy as important issues that need urgent action. In line
89 with this plight, NAGI has formed working groups to find lasting solutions to these issues. There
90 is thus an urgent need for local data on vaccine hesitancy and uptake among HCWs in Cape
91 Town and South Africa as a whole.

92 Prior to COVID-19 pandemic, work related to vaccine hesitancy among HCWs evaluated
93 vaccines most requested by healthcare establishments for staff members, which include
94 influenza vaccines and hepatitis B.

95 HCWs were more likely to recommend vaccination if they were themselves vaccinated. A
96 study in the United Kingdom (UK) showed that nurses who were vaccinated were more likely
97 to recommend vaccination to their peers and other patients (17). A Nigerian study similarly
98 reported that female nurses were more likely to recommend HPV vaccination when they
99 expressed a willingness to be vaccinated themselves (18). Further research in Israel found that
100 physicians were more likely to recommend vaccinations to patients if they accepted the
101 influenza vaccine for themselves (19). Moreover, Canadian study also found that midwives
102 who reported being immunized themselves were more likely to have trust in the safety and
103 efficacy of influenza vaccine, and subsequently recommended vaccination to their colleagues

104 and patients (20). It was also found in a US study that recommending the influenza vaccine to
105 co-workers, patients, or patients' families, was also associated with HCWs themselves being
106 vaccinated (21). HCWs in Iran who intended to be vaccinated against influenza in the next
107 season were also 4.6 times more likely to recommend vaccination to their patients than those
108 who did not intend to be vaccinated (22). However, little is known about the drivers of
109 vaccination hesitancy among HCWs in Cape Town, and the extent of its impact on vaccination
110 coverage; as most research on vaccination hesitancy have been conducted in high-income
111 countries (HICs) (9, 10). In addition, tools to measure determinants of vaccination hesitancy
112 and uptake are scarce and none of the current existing ones have been validated in South Africa.
113 Furthermore, there are no studies on Influenza vaccine hesitancy among HCWs in Cape Town
114 and South Africa in general. A measurement tool for vaccination hesitancy developed in
115 Germany (known as the 5C scale, Appendix 1) has been shown to be valid and easy to
116 administer in Europe and North America (5). The 5C scale contains a series of items (or
117 questions) to assess five determinants of vaccine hesitancy: confidence, complacency,
118 constraints (convenience), rational calculation, and collective responsibility (5). However, as
119 with other vaccination hesitancy measurement tools (6, 7, 8) this scale is based on research
120 conducted in high-income countries and has not been validated in South Africa. This
121 potentially limits its generalizability to healthcare worker vaccination in Cape Town; hence
122 there is need to adapt, pilot and validate this tool in our setting to determine factors associated
123 with both Influenza and COVID-19 vaccines hesitancy among HCWs in the Western Cape,
124 South Africa. This study aims to fill these gaps through developing capacity for vaccination
125 hesitancy research in Cape Town and a validated measurement tool for vaccination hesitancy
126 in this setting. The validated tool would be useful to better understand the burden and causes
127 of vaccination hesitancy among HCWs in South Africa, monitor changes and trends over time
128 and place in the country, and enhance the comparability of research results across the country.

129

130 **Materials and methods**

131 **Aims, design, population, and study setting**

132 The methodological framework for this study is adapted from Betsch and colleagues (5) and
133 the WHO Guide to Tailoring Immunization Program (TIP) (55). Betsch and colleagues found
134 in studies conducted in Germany and the USA that the determinants of vaccine hesitancy vary
135 depending on the vaccine, the target group, and the country of study (5). We will focus this
136 project on HCWs and on two vaccines, the seasonal influenza vaccine, and the COVID-19
137 vaccine. In this cross-sectional study, we aim to understand the extent and determinants of
138 vaccination hesitancy among HCWs in Cape Town and to construct a validated tool to measure
139 the phenomenon of vaccination hesitancy in this population. We will focus on two vaccines:
140 an existing vaccine recommended for HCWs (the seasonal influenza vaccine) and the vaccine
141 for COVID-19 for which HCWs are a priority target population. Cape Town has close to 32.479
142 health care workers according to (Western Cape annual report 2020/2021). By august 2021,
143 the Western Cape Government had administered a cumulative total of 1 426 278 COVID-19
144 vaccines to healthcare workers, The study will take place within the Cape Metro of the Western
145 Cape of South Africa. All healthcare facilities in the Cape Metro (whether providing integrated
146 primary healthcare, level 2, or level 3 services) will be approached for participation in the
147 study, making all healthcare facilities in the Cape Metro eligible for inclusion in the study and
148 thus will avoid selection bias in the recruitment of participants. The City of Cape Town is home
149 to about 4.4 million people, making it the second metro by population size in South Africa and
150 the Metro also prides itself as the tourism hub of the country. Cape Town has a coastline of
151 294km and is also bounded by the Atlantic Ocean to the south and west. The city positions
152 itself in Table Bay, bottom end of the African continent. It is the second largest city in South
153 Africa and the capital of Western Province.

154 Globally, as of 22 May 2022 according to the WHO COVID-19 dashboard [66], there have
155 been 524 339 768 confirmed cases of SARS-CoV-2 infections, the virus that causes COVID-
156 19, including 6 281 260 deaths from COVID-19. A total of 11 752 954 673 vaccine doses have
157 been administered globally by 22 May 2022. In South Africa by 22 May 2022, there have
158 been 3 915 253 confirmed cases of SARS-CoV-2 infections with 100 898 deaths from COVID-
159 19 reported to WHO. As of 22 May 2022, a total of 35 744 528 vaccine doses have been
160 administered in South Africa. In the Western Cape Province, a total of 701 607 confirmed cases
161 of SARS-CoV-2 infections were reported with 22 065 deaths from COVID-19.

162 **The 5C scale tool**

163 The five psychological antecedents of vaccination in the 5C scale are confidence, complacency,
164 constraints or convenience, rational calculation, and collective responsibility (5). *Confidence*
165 refers to the trust in (i) the effectiveness and safety of vaccines, (ii) the system that delivers
166 them, including the reliability and competence of the health services and health professionals,
167 and (iii) the motivations of policy-makers who decide on the need of vaccines (5). The authors
168 of the 5C scale found in Europe and North America that individuals who lack confidence hold
169 negative attitudes towards vaccinations, do not believe that vaccines are safe and effective, and
170 do not trust the system that provides vaccination (5). *Complacency* occurs when “perceived
171 risks of vaccine-preventable diseases are low and vaccination is not deemed a necessary
172 preventive action”(5). Individuals scoring high in complacency do not perceive any risks from
173 vaccine-preventable diseases. *Constraints* refer to practical barriers such as costs and lack of
174 time or access. *Rational calculation* of risks and benefits of vaccination involves extensive
175 searching for information about vaccination. *Collective responsibility* describes the situation
176 whereby people understand the value of, and engage in vaccination, to contribute to herd
177 immunity (5).


178

179 Phases of the study

180

181 Our study will be conducted across four phases as described below

182



183

184

185 **Phase 1: Adaptation of the Original 5C scale to the 5C+ Cape Town Scale**

186 In this phase 1, we aim to gain deeper understanding of vaccine hesitancy among HCWs in

187 Cape Town by engaging with relevant stakeholders. Through such engagement the study team

188 will review the existing items in the 5C scale (6, 7, 8). This will further inform the identification

189 and generation of additional factors and corresponding items in Cape Town, South Africa (5C+

190 Cape Town Scale). The expanded 5C+ Cape Town Scale will be translated into English,

191 isiXhosa, and Afrikaans (Phase 1a). Based on our experience in the region, the added items

192 will include willingness to be vaccinated and the compatibility of vaccination with religious

193 beliefs. We will send the adapted 5C scale (the 5C+ Cape Town Scale) to at least five vaccine

194 experts and HCWs in South Africa, to get feedback on whether the items are easy to understand.

195 This engagement will help to ensure the face validity and comprehensibility of the items of the

196 5C+ Cape Town Scale (56). HCWs will then complete a questionnaire on their attitudes to

197 COVID-19 and influenza vaccines, including willingness to get vaccinated (Phase 1b). The
198 survey will be conducted both face-to-face and web-based in accordance with the COVID-19
199 regulation in place.

200 **Phase 2: Validation of the 5C+ Cape Town Scale**

201 The objective of this phase is to assess the reliability, construct, concurrent, and predictive
202 validity of the adapted 5C scale for HCWs (the 5C+ Cape Town scale), and to develop a short
203 scale (61) (Phase 2a). The validation procedure is necessary to ensure that the items assessing
204 one of the original 5C factors produce similar results after adaptation in phase 1a and 1b as
205 compared to the original version. Based on the findings, we may further refine the 5C items for
206 the Cape Town specific scale (5C+ Cape Town) for further testing (Phase 2b). Construct
207 validity queries whether the tool assesses what it aims to assess. Convergent validity will refer
208 to the extent to which a measure correlates with other indicators of the same construct.
209 Discriminant validity will refer to the extent to which a measure does not correlate with
210 indicators of other constructs that are theoretically or empirically distinct. Concurrent validity
211 will involve relating a measure to criteria assessed at the same time as the measure itself.
212 Predictive validity will encompass associations with criteria that are assessed at some point in
213 the future (5).

214 **Phase 3: Stakeholders' engagement**

215 The objective of Phase 3 will be to share, discuss and obtain feedback on the findings from
216 phases 1 and 2, including how the findings can be promoted for use within policy, practice, and
217 research. We will identify and generate a list of key groups and individuals involved in the
218 design, planning and implementation of healthcare worker vaccination (17). This will include
219 policymakers, program and facility managers, professional associations, oversight, and
220 advisory bodies, HCW unions, and HCWs themselves. The list will be developed iteratively
221 by the research team, drawing on their collective knowledge of the relevant stakeholders,

222 scoping of the literature, and team discussions. The methodology for developing the
223 stakeholder list will be guided by the methods developed in a previous study to identify a
224 complex multiple stakeholder reference sample (20)

225 Engagement workshops will then be conducted with a selection of individuals from identified
226 stakeholder groups. We will employ a maximum variation purposive sampling approach (21)
227 to ensure that workshop participant groups comprise ‘information-rich’ cases (i.e. individuals
228 who are especially knowledgeable about or experienced in HCW vaccination) and reflect wide
229 ranging socio-demographic characteristics and stakeholder groups.

230 The stakeholder engagement workshops will be conducted face-to-face or online, depending
231 on existing Covid-19 guidelines. Each workshop will include approximately 10-15
232 participants. The number of workshops conducted will be determined iteratively, depending on
233 the response rate amongst stakeholders and the findings that emerge.

234 The workshop will begin with a presentation of the findings from phases 1 and 2. Thereafter
235 participants will be encouraged to provide feedback, including their views about: the extent
236 and determinants of vaccination hesitancy among HCWs identified by the study, whether these
237 findings resonate (or not) with their own experiences, potential issues not identified by the
238 study, the 5C+ Cape Town Scale (including its acceptability and usability in their local
239 settings), as well as the potential implications of the study findings. The discussions will also
240 obtain participants views and experiences regarding how the findings can be promoted for use
241 within policy, practice, and research to strengthen the immunisation program among HCWs.

242 We will use multiple participatory methods to gather participant input and facilitate two-way
243 engagement between the researchers and stakeholders (22) Potential techniques to be used
244 include, brainstorming, meta-planning, listing, mind mapping, and ranking exercises and will
245 comprise both large group discussions and small break-out group work. We will carefully pre-
246 plan the composition of the small groups, considering the power-dynamics between

247 stakeholder groups and how the views of more marginalised individuals can be properly
248 expressed.

249 With the permission of participants, all workshops will be audio-recorded and transcribed
250 verbatim, and all personal identifying information will be removed from transcripts. The
251 anonymised transcripts will be downloaded into NVivo, a software programme that aids with
252 the management and analysis of qualitative data. The data will be analysed through a thematic
253 analysis, using the phases described by Braun and Clarke (23). The analysis will identify key
254 themes regarding stakeholders' views about the findings and strategies to enhance their uptake,
255 as well as their views about the 5C+ Cape Town Scale and its usability. One researcher will
256 lead the analysis, with regular discussion and feedback from other researchers.

257 **Healthcare workers recruitment and sample size estimation**

258 All HCWs working in Cape Town will be eligible for inclusion. This will include nurses,
259 medical doctors, pharmacists, hospital administrative personals, health researchers etc.
260 Permission has been received from all the relevant authorities (including the University of Cape
261 Town Human Research Ethics Committee, the Western Cape Provincial Department of Health.
262 We will contact facility managers who will assist in identifying potential participants. The
263 purpose of the study will be explained to both the managers and the potential participants.
264 The total sample size for the validation survey will be at least 300 HCWs, based on best practice
265 recommendations for scale validation and performance of exploratory factor analyses (63).
266 Given that the assessment of validity is based on the inspection of correlation patterns, studies
267 suggest using a sample comprising at least 300 participants, which will allow detecting small
268 correlations ($r=0.2$) with at least 95% power (62). While we will aim to recruit a sample size
269 that is diverse and representative of HCWs in Cape Town, we are also mindful of the fact that
270 representative sampling is a very complex endeavour and highly context-specific among
271 HCWs during the pandemic period (64, 65).

272 **Data collection and data Management**

273 This study will have no direct impact on clinic and hospital healthcare operations. The study
274 will be performed with minimal direct contact with staff at healthcare facilities.

275 Healthcare workers will complete the consent form and questionnaire either as a hardcopy
276 (provided to healthcare facilities) or through an online platform whereby the data will be
277 directly captured onto the Research Electronic Data Capture (REDCap) database. The duration
278 for completion of the consent form and questionnaire will be about 20 minutes which can be
279 done at the convenience of the HCW. The 5C questionnaire designed to capture 23 exploratory
280 variables including socio-demographic characteristics and attitudes of HCWs towards COVID-
281 19 and influenza vaccination has been designed (Appendix 2).

282 **Expected outcome**

283 The primary outcome of this study is a validated tool to measure vaccination hesitancy and
284 acceptance among HCWs in Cape Town, with focus on COVID-19 and influenza vaccines.
285 The adapted and validated long and short scales have the potential to be applicable to other
286 parts of South Africa, to other target groups in the country, and to vaccination programs in
287 general. This would be an important contribution to science, as no tool to measure the
288 determinants of vaccination hesitancy and acceptance among HCWs has been previously tested
289 in an African country. The secondary outcome will involve assessing the proportion and related
290 risk factors of COVID-19 and influenza vaccines hesitancy and acceptance among HCWs.
291 Lastly, the tertiary outcome will evaluate the process, barriers, and enablers of implementing
292 the 5C+ Cape-Town scale in South Africa and other similar health settings in the global south.

293 **Statistical analyses**

294 In the analyses, we will first assess the reliability of the 5C+ Cape Town scale (by assessing
295 Cronbac's alpha) and then determine its validity, i.e., find out whether it measures what it

296 intends to measure. For this, we will investigate whether the 5C+ factors are associated with
297 theoretically similar constructs (e.g. confidence should correlate with attitude) (5). To do so,
298 we will calculate Pearson's correlations between each 5C+ factor and the validation constructs.
299 The pattern of results will inform the item selection process – both reliability and validity will
300 be optimized in this process.

301 Then we will assess which Cape Town 5C+ factors are associated with vaccination behaviour
302 or intention, and how strong these relations are. For vaccination behaviour we will find out for
303 each participant if he/she has previously been vaccinated against seasonal influenza and if
304 he/she intends to take the COVID-19 vaccine and influenza vaccine during the next influenza
305 season. For the survey, we will categorise participants as willing or unwilling to vaccinate when
306 a vaccine will be available to them. For descriptive analysis, we will summarise responses as
307 counts and percentages for categorical variables and means with their standard deviations (or
308 medians and respective inter quartile ranges) as appropriate for continuous variables. We will
309 run the Shapiro-wilks test to assess the normality. Analysis of the variance (ANOVA), chi-
310 square tests, and equivalents will be conducted as appropriate for group comparisons. Logistic
311 regression models will also be performed to assess the association between each item of the 5C
312 instrument and COVID-19 and influenza vaccines hesitancy and acceptance.

313 Finally, we will develop a short scale by selecting one item per subscale that best represents
314 each subscale. The one item that correlates with the validation construct in the same direction
315 and to a similar extent as the whole scale will be selected. As a result of this process, we will
316 have a validated long and short scale for measuring vaccine hesitancy and acceptance among
317 HCWs in Cape Town, each having several subscales that capture the psychological
318 determinants of vaccination in a culturally appropriate and adapted way. Spearman's rank
319 correlation coefficient will be used to calculate concurrent validity between the 5C original
320 scale and the 5C+ Cape Town long and short scales. A two-sample t-test will be used to

321 compare the 5C+ Cape Town group scales/scores to the original. For nonparametric data,
322 Spearman's rho, Inter-Class Correlation Coefficient (ICC), and Wilcoxon paired test will be
323 used for reliability assessment. Cronbach's alpha will be used to determine internal consistency
324 for the total score. We will consider a p-value < 0.05 to indicate statistically significant results.
325 All analyses will be performed in R Foundation for Statistical Computing, Vienna, Austria))
326 V4.0.5 software.

327 **Ethical declaration**

328 Ethical approval for this study was obtained from the University of Cape Town Human
329 Research Ethics Committee (HREC Ref# (858/2020.)). Furthermore, administrative permission
330 has been obtained from the Western Cape Provincial Department of Health (WC, (#
331 WC_202101_014), and the management of the various hospital where data will be collected.
332 The study objectives will be clearly explained in an information sheet, before the consent form
333 (Appendix 3) is signed and each participant will be made to know that they can discontinue
334 their participation at any time. Data will be used only from participants who signed the consent
335 form before participation. Confidentiality will be maintained by collecting only participant
336 demographics without names and other participant information protected. Further to that, only
337 age ranges will be used for further data processing with no information that may lead to
338 identification of any participant. The risks associated with this study are minimal for
339 participants.

340

341 **Discussion and conclusion**

342 Our study builds on the 5C scale described previously (5). The 5C is suitable for this study
343 because it captures multiple dimensions of vaccine hesitancy; extending the scope of existing
344 vaccine hesitancy measuring scales that focus primarily on confidence-related aspects. Another

345 advantage of the 5C scale is that it assesses five determinants of vaccination with only 15
346 questions, and a shorter version of only five questions (5). Adapting and piloting this
347 instrument in our setting will then allow us to understand whether the 5C scale is applicable to
348 HCWs in South Africa. This question matters because studies in Western countries have shown
349 that the determinants of vaccine hesitancy vary depending on the target group, the country of
350 study, and the vaccine (5) and that vaccine hesitancy among HCWs might reduce effort to curb
351 the ongoing pandemic.

352

353 **Vaccine decision making process and HCWs**

354 Vaccination is often cited as one of the most effective ways of controlling infectious diseases
355 (11). However, while most people vaccinate according to the recommended schedule, this
356 success is being challenged by individuals and groups who choose to delay or refuse vaccines
357 (12). HCWs have had different responses to this changing environment. Certain health facilities
358 have dropped patients if they refuse vaccination (13, 12), making the case that it puts their other
359 patients at risk, while in other hospitals or clinics, some HCWs decided to delay vaccination or
360 administer partial doses, in order to protect the trust relationship with their patient, although
361 recognizing there is no clinical evidence to support such an approach (14). The vaccination
362 decision-making process includes people who agree to be vaccinated, because they see it as the
363 norm, and those that take their time weighing up the pros and cons of vaccination, talking with
364 family, friends, or members of their community, searching the internet, and asking their HCWs
365 for advice. The relevance of HCWs vaccine hesitancy is a process that has been well
366 documented (15). HCWs are one of the strongest influences in vaccination decisions and it is
367 on this basis that this study is grounded. Despite variations in reasons for hesitancy across
368 geographies and vaccines among HCWs hesitancy, there are common themes that emerge
369 globally (12, 16).

370 The WHO Strategic Advisory Group of Experts on Immunization (SAGE) convened a working
371 group to investigate the nature and scope of vaccine hesitancy, which has created a model of
372 determinants of vaccine hesitancy organized around three domains, namely: (1) contextual
373 influences, (2) individual or social group influences, and (3) vaccine and vaccination-specific
374 issues (12). All three domains include the influence of others on vaccine hesitancy. Domain 1
375 (contextual influences) includes influential leaders and individuals; domain 2 (individual or
376 social group influences) includes personal experience with and trust in the health system and
377 provider; and domain 3 (vaccine and vaccination-specific issues) includes the role of HCWs
378 which is the focus of this study. In a study about HPV vaccination in Cameroon, the most
379 important factors considered among nurses when deciding to recommend the vaccine included
380 understanding the effectiveness and safety of the vaccine (27). In another example, a study on
381 HCWs vaccine hesitancy in the USA found that those who were not confident in the vaccine's
382 efficacy and protective value were less likely to recommend it to patients or accept it
383 themselves (21). Irrespective of the influence of HCWs vaccination behaviour on peers and
384 others, the attitudes of HCWs towards vaccination may have a powerful influence. For
385 example, a study about doctors' attitudes towards measles, mumps and rubella (MMR)
386 vaccination in Denmark illustrated that the average vaccination rate in practices with
387 unreservedly positive attitudes about vaccination was 85%, compared with 69% in practices
388 with more guarded attitudes (23).

389 **Strengths and limitations of the study**

390 **Study strengths**

391 With a broad range of scenarios, it is expected that the research will generate evidence that is
392 potentially applicable to other parts of South Africa. This study will produce relevant
393 knowledge and has the potential for effecting policy changes (56). A complex web of
394 influences and interactions affect the degree to which evidence is used by policymakers and

395 managers. Among the many critical factors, the involvement of, and buy-in from, policymakers
396 and managers at an early stage in the research is an essential element for ensuring that emerging
397 evidence can be disseminated in timely and appropriate formats. This is the reason why we
398 have already started engagement with the management of the healthcare facilities in Cape
399 Town Metro.

400 Vaccine hesitancy is complex and context-specific, varying across time, place, and vaccines.
401 It may be related to a specific product such as a new vaccine, new vaccine formulation, or new
402 route of administration of a vaccine. Most of the research on the topic comes from HICs and
403 not much is known about this issue in low and middle-income countries generally and South
404 Africa specifically.

405 This study also draws on the WHO Guide to Tailoring Immunization Program (TIP) (55). The
406 TIP framework takes a broader approach to other measurement tools and helps to 1) identify
407 and prioritize vaccine hesitant populations and subgroups, 2) diagnose and distinguish the
408 demand and supply-side barriers to vaccination in these populations, and 3) design evidence-
409 informed responses to vaccine hesitancy appropriate to the setting, context, and hesitant
410 population. This framework will help us to understand HCW vaccine hesitancy and better
411 distinguish it from the broader range of barriers and facilitators facing HCWs vaccination.

412 **Study limitations**

413 The study limitations include that if participants lack understanding of certain questions, they
414 will not complete the entire questionnaire for those that will complete the questionnaire online.
415 This may lead to some exclusions for incomplete data. The second limitation is that the study
416 will be cross-sectional assessing vaccine hesitancy at a single time point. There is possibility
417 that attitudes of HCWs about vaccine can change over time.

418 **Data availability and dissemination plans**

419 **Dissemination plans**

420 The results of this study will be published in scientific journals to allow researchers from sub-
421 Saharan Africa and other countries that have not yet tested the 5C model to be able to study
422 vaccine hesitancy in their respective settings. Moreover, the outcomes of these study will
423 inform HCWs information sessions within our hospitals and teaching hospitals and may further
424 inform re-enforcement of lectures on immunisation and vaccines. The outcomes will further be
425 summarised to inform policy makers on how to better improve campaigns for COVID-19 and
426 influenza vaccination among HCWs.

427 **Data availability Statement**

428 Main research design and tool will be made freely available to the broader academic
429 community and public. Focus will be placed on data management and protection of participants
430 information as well as faithful and reproducible record keeping, with an emphasis on
431 transparency and accountability in methods utilised. Primary outcome being identification of
432 factors associated with vaccine hesitancy and affecting vaccine uptake by healthcare workers.
433 The results will be documented in text, plots, and images. Findings will be legible, reasonably
434 organized, and sufficiently detailed for future use by other researchers wishing to reproduce
435 the outcome. Research Electronic Data Capture (REDCap) computer software will be used to
436 capture, store and generate data. All raw data in electronic format will be stored in an organised
437 fashion and widely used and accessible formats will be employed. All stored electronic data,
438 updated frequently, will be continuously backed up to external (including cloud-based) media.
439 Detail results of the main research products will appear online in digital format in text, tables,
440 plots, and images in peer-reviewed journal articles and/or conference proceedings. Records
441 will be durable, accessible, and made safe from tampering or falsification.

442 **Conclusion**

443 In this survey of vaccine hesitancy among HCWs, we will adapt, pilot, and validate the 5C
444 scale instrument among HCWs in South Africa. By doing so, we will gain knowledge on the

445 extent and determinants of vaccination hesitancy among HCWs in an African context. This
446 may facilitate other researchers to study this complex and context-specific phenomenon of
447 vaccination hesitancy in South Africa and generally in Africa. This would expand the evidence
448 base on vaccination hesitancy in Africa and enhance the generalizability of current theoretical
449 causal models of vaccination hesitancy. Such knowledge will enable us and other researchers
450 in the future to design interventions to reduce vaccination hesitancy, which are evidence-based,
451 contextually appropriate, and focused on causal mechanisms, thus improving their
452 effectiveness, cost-efficiency, and acceptability.

453

454 **Abbreviations**

455 5C Scale: Tool to measure five determinants of vaccine hesitancy (confidence, complacency,
456 constraints, rational calculation, and collective responsibility)

457 5C+ Scale: 5C scale adapted to Cape Town

458 CHC: Community Health Center

459 GVAP: Global Vaccine Action Plan

460 HCW: Healthcare Workers

461 HICs: High Income Countries

462 HREC: Human Research Ethics Committee

463 MMR: Measles, Mumps and Rubella

464 NAGI: National Advisory Group on Immunization

465 SAGE: Strategic Advisory Group of Experts on Immunization

466 SWOT: Strengths Weaknesses, Opportunities, and Threats

467 TIP: Tailoring Immunization Program

468 UK: United Kingdom

469 UCT: University of Cape Town

- 470 USA: United States of America
- 471 WP: Western Cape province
- 472 WHO: World Health Organization?

473 **References**

- 474 1. World Health Organization. Ten threats to global health in 2019.
475 <https://www.who.int/emergencies/ten-threats-to-global-health-in-2019> [Internet].
476 World Health Organisation (WHO). 2019. p. 1–18. Available from:
477 [https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-](https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019)
478 [2019%0Ahttps://www.who.int/news-room/feature-stories/ten-threats-to-global-health-](https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019)
479 [in-2019%0](https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019)
- 480 2. Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the Expanded Programme
481 on Immunization in Africa: Looking beyond 2015. *PLoS Med*. 2013 Mar;10(3).
- 482 3. Larson HJ. The state of vaccine confidence. Vol. 392, *The Lancet*. 2018. p. 2244–6.
- 483 4. MacDonald NE, Eskola J, Liang X, Chaudhuri M, Dube E, Gellin B, et al. Vaccine
484 hesitancy: Definition, scope and determinants. *Vaccine*. 2015 Aug;33(34):4161–4.
- 485 5. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence:
486 Development of a measure assessing the 5C psychological antecedents of vaccination.
487 *PLoS One*. 2018;13(12):1–32.
- 488 6. Larson HJ, Jarrett C, Schulz WS, Chaudhuri M, Zhou Y, Dube E, et al. Measuring
489 vaccine hesitancy: The development of a survey tool. *Vaccine*. 2015 Aug;33(34):4165–
490 75.
- 491 7. Shapiro GK, Tatar O, Dube E, Amsel R, Knauper B, Naz A, et al. The vaccine hesitancy
492 scale: Psychometric properties and validation. *Vaccine*. 2018 Jan;36(5):660–7.
- 493 8. Opel DJ, Taylor JA, Mangione-Smith R, Solomon C, Zhao C, Catz S, et al. Validity and
494 reliability of a survey to identify vaccine-hesitant parents. *Vaccine*. 2011
495 Sep;29(38):6598–605.
- 496 9. Cooper S, Okeibunor JC, Wiyeh A, Wiysonge CS. Knowledge advances and gaps on

- 497 the demand side of vaccination. Vol. 19, *The Lancet Infectious Diseases*. Lancet
498 Publishing Group; 2019. p. 13–5.
- 499 10. Cooper S, Betsch C, Sambala EZ, Mchiza N, Wiysonge CS. Vaccine hesitancy—a
500 potential threat to the achievements of vaccination programmes in Africa. Vol. 14,
501 *Human Vaccines and Immunotherapeutics*. Taylor and Francis Inc.; 2018. p. 2355–7.
- 502 11. Maduka O, Akpan G, Maleghemi S. Using Android and Open Data Kit Technology in
503 Data Management for Research in Resource-Limited Settings in the Niger Delta Region
504 of Nigeria: Cross-Sectional Household Survey. *JMIR mHealth uHealth*. 2017
505 Nov;5(11):e171.
- 506 12. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine
507 hesitancy around vaccines and vaccination from a global perspective: A systematic
508 review of published literature, 2007-2012. Vol. 32, *Vaccine*. Elsevier BV; 2014. p.
509 2150–9.
- 510 13. Mejia B. Doctors turning away unvaccinated children - Los Angeles Times. 2015.
- 511 14. Kempe A, O’Leary ST, Kennedy A, Crane LA, Allison MA, Beaty BL, et al. Physician
512 response to parental requests to spread out the recommended vaccine schedule.
513 *Pediatrics*. 2015 Apr;135(4):666–77.
- 514 15. Wiley KE, Massey PD, Cooper SC, Wood N, Quinn HE, Leask J. Pregnant women’s
515 intention to take up a post-partum pertussis vaccine, and their willingness to take up the
516 vaccine while pregnant: A cross sectional survey. *Vaccine*. 2013 Aug;31(37):3972–8.
- 517 16. Boudier F, Way D, Löfstedt R, Evensen D. Transparency in Europe: A Quantitative
518 Study. *Risk Anal*. 2015 Jul;35(7):1210–29.
- 519 17. Larson HJ, Smith DMD, Paterson P, Cumming M, Eckersberger E, Freifeld CC, et al.
520 Measuring vaccine confidence: Analysis of data obtained by a media surveillance
521 system used to analyse public concerns about vaccines. *Lancet Infect Dis*. 2013

- 522 Jul;13(7):606–13.
- 523 18. Zhang J, While AE, Norman IJ. Nurses’ knowledge and risk perception towards seasonal
524 influenza and vaccination and their vaccination behaviours: A cross-sectional survey.
525 Int J Nurs Stud. 2011 Oct;48(10):1281–9.
- 526 19. Makwe CC, Anorlu RI. Knowledge of and attitude toward human papillomavirus
527 infection and vaccines among female nurses at a tertiary hospital in Nigeria. Int J
528 Womens Health. 2011;3(1):313–7.
- 529 20. Livni G, Chodik G, Yaari A, Tirosh N, Ashkenazi S. Attitudes, knowledge and factors
530 related to acceptance of influenza vaccine by pediatric healthcare workers. J Pediatr
531 Infect Dis. 2008 Jan;3(2):111–7.
- 532 21. Lee T, Saskin R, McArthur M, McGeer A. Beliefs and practices of Ontario midwives
533 about influenza immunization. Vaccine. 2005 Feb;23(13):1574–8.
- 534 22. LaVela SL, Smith B, Weaver FM, Legro MW, Goldstein B, Nichol K. Attitudes and
535 Practices Regarding Influenza Vaccination Among Healthcare Workers Providing
536 Services to Individuals With Spinal Cord Injuries and Disorders. Infect Control Hosp
537 Epidemiol. 2004 Nov;25(11):933–40.
- 538 23. Askarian M, Khazaeipour Z, McLaws ML. Facilitators for influenza vaccination uptake
539 in nurses at the Shiraz University of Medical Sciences. Public Health. 2011
540 Aug;125(8):512–7.
- 541 24. Trier H. Doctors’ attitudes and MMR-vaccination. Scand J Prim Health Care.
542 1991;9(1):29–33.
- 543 25. Baron-Epel O, Bord S, Madjar B, Habib S, Rishpon S. What lies behind the low rates of
544 vaccinations among nurses who treat infants? Vaccine. 2012 May;30(21):3151–4.
- 545 26. Marcu A, Rubinstein H, Michie S, Yardley L. Accounting for personal and professional
546 choices for pandemic influenza vaccination amongst English healthcare workers.

- 547 Vaccine. 2015;33(19):2267–72.
- 548 27. Zhang J, While AE, Norman IJ. Nurses' vaccination against pandemic H1N1 influenza
549 and their knowledge and other factors. *Vaccine*. 2012 Jul;30(32):4813–9.
- 550 28. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Welty T, et al. Awareness,
551 knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in
552 Cameroon: An exploratory study. *Int J Nurs Stud*. 2013 Oct;50(10):1399–406.
- 553 29. Duval B, Gilca V, Boulianne N, Pielak K, Halperin B, Simpson MA, et al. Cervical
554 cancer prevention by vaccination: nurses' knowledge, attitudes and intentions. *J Adv
555 Nurs*. 2009 Mar;65(3):499–508.
- 556 30. Brabin L, Stretch R, Roberts SA, Elton P, Baxter D, McCann R. The school nurse, the
557 school and HPV vaccination: A qualitative study of factors affecting HPV vaccine
558 uptake. *Vaccine*. 2011 Apr;29(17):3192–6.
- 559 31. Gilca V, Boulianne N, Dubé E, Sauvageau C, Ouakki M. Attitudes of nurses toward
560 current and proposed vaccines for public programs: A questionnaire survey. *Int J Nurs
561 Stud*. 2009 Sep;46(9):1219–35.
- 562 32. Hoque ME, Monokoane S, Van Hal G. Knowledge of and attitude towards human
563 papillomavirus infection and vaccines among nurses at a tertiary hospital in South
564 Africa. *J Obstet Gynaecol (Lahore)*. 2014 Feb;34(2):182–6.
- 565 33. Ishola DA, Permalloo N, Cordery RJ, Anderson SR. Midwives' influenza vaccine
566 uptake and their views on vaccination of pregnant women. *J Public Heal (United
567 Kingdom)*. 2013 Dec;35(4):570–7.
- 568 34. Austvoll-Dahlgren A, Helseth S. Public health nurses' barriers and facilitators to the use
569 of research in consultations about childhood vaccinations. *Scand J Caring Sci*. 2012
570 Jun;26(2):271–8.
- 571 35. Ravlija J, Ivankovic A. Importance of health workers' communication in immunisation

- 572 programmes. *HealthMED*. 2012;6(2):672–7.
- 573 36. Hollmeyer H, Hayden F, Mounts A, Buchholz U. Review: Interventions to increase
574 influenza vaccination among healthcare workers in hospitals. *Influenza Other Respi*
575 *Viruses*. 2013 Jul;7(4):604–21.
- 576 37. Wicker S, Doerr HW, Gottschalk R, Rabenau HF, Allwinn R. Influenza: Akzeptanz der
577 schutzimpfung bei medizinischem personal - Auswertung zur influenzasaison
578 2006/2007. *Dtsch Medizinische Wochenschrift*. 2007;132(33):1683–7.
- 579 38. Launay O, Le Strat Y, Tosini W, Kara L, Quelet S, Lévy S, et al. Impact of free on-site
580 vaccine and/or healthcare workers training on hepatitis B vaccination acceptability in
581 high-risk subjects: A pre-post cluster randomized study. *Clin Microbiol Infect*. 2014
582 Oct;20(10):1033–9.
- 583 39. Bonaccorsi G, Lorini C, Santomauro F, Guarducci S, Pellegrino E, Puggelli F, et al.
584 Predictive factors associated with the acceptance of pandemic and seasonal influenza
585 vaccination in health care workers and students in Tuscany, Central Italy. *Hum Vaccin*
586 *Immunother*. 2013 Dec;9(12):2603–12.
- 587 40. Ribner BS, Hall C, Steinberg JP, Bornstein WA, Chakkalakal R, Emamifar A, et al. Use
588 of a Mandatory Declination Form in a Program for Influenza Vaccination of Healthcare
589 Workers. *Infect Control Hosp Epidemiol*. 2008 Apr;29(4):302–8.
- 590 41. Talbot TR, Dellit TH, Hebden J, Sama D, Cuny J. Factors Associated with Increased
591 Healthcare Worker Influenza Vaccination Rates: Results from a National Survey of
592 University Hospitals and Medical Centers. *Infect Control Hosp Epidemiol*. 2010
593 May;31(5):456–62.
- 594 42. Thoon KC CC. Survey of healthcare workers' attitudes, beliefs and willingness to
595 receive the 2009 pandemic influenza A (H1N1) vaccine and the impact of educational
596 campaigns - PubMed. *Ann Acad Med Singapore*. 2010;1(39):(4):307.

- 597 43. Rakita RM, Hagar BA, Crome P, Lammert JK. Mandatory Influenza Vaccination of
598 Healthcare Workers: A 5-Year Study. *Infect Control Hosp Epidemiol*. 2010
599 Sep;31(9):881–8.
- 600 44. Chyderiotis S, Seringe E, Blanckaert K, Guet L, Kadi Z, Astagneau P. Influenza
601 vaccination coverage in healthcare workers during the 2014-2015 season. *Antimicrob
602 Resist Infect Control*. 2015;4(Suppl 1):P18.
- 603 45. Harbarth S, Siegrist C-A, Schira J-C, Wunderli W, Pittet D. Influenza Immunization:
604 Improving Compliance of Healthcare Workers. *Infect Control Hosp Epidemiol*. 1998
605 May;19(5):337–42.
- 606 46. Organization WH. WHO | SAGE working group dealing with vaccine hesitancy (March
607 2012 to November 2014). WHO. 2015;
- 608 47. Bedford H, Attwell K, Danchin M, Marshall H, Corben P, Leask J. Vaccine hesitancy,
609 refusal and access barriers: The need for clarity in terminology. *Vaccine*. 2018
610 Oct;36(44):6556–8.
- 611 48. Peretti-Watel P, Larson HJ, Ward JK, Schulz WS, Verger P. Vaccine hesitancy:
612 Clarifying a theoretical framework for an ambiguous notion. *PLoS Curr*. 2015
613 Feb;7(OUTBREAKS).
- 614 49. Oduwole EO, Pienaar ED, Mahomed H, Wiysonge CS. Current tools available for
615 investigating vaccine hesitancy: A scoping review protocol. *BMJ Open*. 2019;9(12).
- 616 50. Opel DJ, Mangione-Smith R, Taylor JA, Korfiatis C, Wiese C, Catz S, et al.
617 Development of a survey to identify vaccine-hesitant parents: The parent attitudes about
618 childhood vaccines survey. *Hum Vaccin*. 2011;7(4).
- 619 51. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends
620 in vaccine confidence and investigating barriers to vaccine uptake: a large-scale
621 retrospective temporal modelling study. *Lancet [Internet]*. 2020;396(10255):898–908.

- 622 Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)31558-0](http://dx.doi.org/10.1016/S0140-6736(20)31558-0)
- 623 52. Larson HJ, Schulz WS, Tucker JD, Smith DMD. Measuring vaccine confidence:
624 Introducing a global Vaccine Confidence Index. *PLoS Curr.* 2015;7(OUTBREAKS).
- 625 53. Gilkey MB, Magnus BE, Reiter PL, McRee AL, Dempsey AF, Brewer NT. The
626 Vaccination Confidence Scale: A brief measure of parents' vaccination beliefs. *Vaccine*
627 [Internet]. 2014;32(47):6259–65. Available from:
628 <http://dx.doi.org/10.1016/j.vaccine.2014.09.007>
- 629 54. Sarathchandra D, Navin MC, Largent MA, McCright AM. A survey instrument for
630 measuring vaccine acceptance. *Prev Med (Baltim) [Internet]*. 2018;109(January):1–7.
631 Available from: <https://doi.org/10.1016/j.yjpm.2018.01.006>
- 632 55. Health Organization W, Office for Europe R. The Guide to Tailoring Immunization
633 Programmes (TIP) Increasing coverage of infant and child vaccination in the WHO
634 European Region. 2013.
- 635 56. Grimshaw JM, Eccles MP, Lavis JN, Hill SJ, Squires JE. Knowledge translation of
636 research findings. *Implement Sci.* 2012 Aug;7(1):50.
- 637 57. Dizon JM, Grimmer K, Machingaidze S, McLaren P, Louw Q. Mapping South African
638 allied health primary care clinical guideline activity: Establishing a stakeholder
639 reference sample. *Heal Res Policy Syst.* 2016 Oct;14(1):77.
- 640 58. Patton MQ. *Qualitative Research & Evaluation Methods*. 2001 Sage Publications.
641 Thousand Oaks, California. 2014.
- 642 59. UNAIDS. Good participatory practice guidelines for biomedical HIV prevention trials.
643 *Vaccine.* 2007;68.
- 644 60. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol.*
645 2006;3(2):77–101.
- 646 61. Simms LJ. *Classical and Modern Methods of Psychological Scale Construction*. Soc

- 647 Personal Psychol Compass. 2008 Jan;2(1):414–33.
- 648 62. Betsch C, Habersaat KB, Deshevoi S, Heinemeier D, Briko N, Kostenko N, et al. Sample
649 study protocol for adapting and translating the 5C scale to assess the psychological
650 antecedents of vaccination. *BMJ Open* [Internet]. 2020 [cited 2020 Oct 28];10:34869.
651 Available from: <http://bmjopen.bmj.com/>
- 652 63. Anthoine E. Sample size used to validate a scale: a review of publications on n... -
653 PubMed - NCBI. *Health Qual Life Outcomes* [Internet]. 2014;1–10. Available from:
654 <http://www.ncbi.nlm.nih.gov/pubmed/25492701>
- 655 64. Africa. ND of HS. *Demographic and Health Survey 2016*. 2016.
- 656 65. Dhs M. *Sénégal Enquête Démographique et de Santé à Indicateurs Multiples*. 2011 Sep;
657 66 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (Accessed 22 May
658 2022)
- 659
- 660
- 661
- 662
- 663
- 664
- 665
- 666
- 667
- 668
- 669
- 670
- 671

672 **Appendix**

673 1. Original 5C scale

674 2. Questionnaire

675 3. Informed consent form